Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

b. braun melsungen - gelatine - infusionsvæske, opløsning - 4 %

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - tick-borne encephalitis virus antigen (neudoerfl stamme), inaktiveret - injektionsvæske, suspension, fyldt injektionssprøjte - 2,4 mikrogr./0,5 ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - gelatine - infusionsvæske, opløsning - 40 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - tick-borne encephalitis virus antigen (neudoerfl stamme), inaktiveret - injektionsvæske, suspension, fyldt injektionssprøjte - 1,2 mikrog./0,25 ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - gelatine - infusionsvæske, opløsning - 40 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

intervet international b.v. - live myxom vektoriserede rhd virusstamme, 009, live myxom vektoriserede rhd virus stamme mk1899 - immunologicals for dyr af hareordenen - kaniner - til aktiv immunisering af kaniner fra 5 ugers alderen, og frem for at reducere dødelighed og kliniske tegn på myxomatosis og rabbit haemorrhagic disease (rhd), der er forårsaget af klassisk rhd virus (rhdv1) og rhd type 2-virus (rhdv2).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - svin - til aktiv immunisering af svin fra 7 uger gamle og fremefter for at forhindre dødelighed og reducere infektion og sygdom forårsaget af klassisk svinepestvirus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.